To profile the functional impact and therapeutic relevance of BRCA1 variants, we developed a relatively simple drug sensitivity assay (Figure 3A–B) using the BRCA1-deficient, triple negative MDA-MB-436 breast cancer cells (Elstrodt et al., 2006). This evidence concerns the gene BRCA1 and breast carcinoma.